Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christodoulos Papadopoulos

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
The American Journal of Cardiology|October 19, 2020
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of InterestDimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Nefrologia|November 27, 2022
Acute kidney injury with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: Foe or friend?Dimitrios Patoulias, Christodoulos Papadopoulos, Fotios Siskos, et al.
Archives of Medical Sciences. Atherosclerotic Diseases|July 18, 2022
Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational studyDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemicDimitrios Patoulias, Christodoulos Papadopoulos, Aristi Boulmpou, et al.
Coronary Artery Disease|November 30, 2021
Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetesDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
European Journal of Internal Medicine|December 31, 2021
"Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?"Dimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
The American Journal of Cardiology|January 28, 2022
Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery DiseaseDimitrios Patoulias, George Kassimis, Michael Doumas, et al.
Acta Diabetologica|August 21, 2020
Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerationsDimitrios Patoulias, Alexandra Katsimardou, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology|August 17, 2022
Updated Meta-Analysis Assessing the Cardiovascular Efficacy of TirzepatideDimitrios Patoulias, Christodoulos Papadopoulos, Nikolaos Fragakis, et al.
Nefrologia|December 9, 2022
Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fractionDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
The American Journal of Cardiology|October 19, 2020
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of InterestDimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Nefrologia|November 27, 2022
Acute kidney injury with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: Foe or friend?Dimitrios Patoulias, Christodoulos Papadopoulos, Fotios Siskos, et al.
Archives of Medical Sciences. Atherosclerotic Diseases|July 18, 2022
Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational studyDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemicDimitrios Patoulias, Christodoulos Papadopoulos, Aristi Boulmpou, et al.
Coronary Artery Disease|November 30, 2021
Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetesDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
European Journal of Internal Medicine|December 31, 2021
"Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?"Dimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
The American Journal of Cardiology|January 28, 2022
Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery DiseaseDimitrios Patoulias, George Kassimis, Michael Doumas, et al.
Acta Diabetologica|August 21, 2020
Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerationsDimitrios Patoulias, Alexandra Katsimardou, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology|August 17, 2022
Updated Meta-Analysis Assessing the Cardiovascular Efficacy of TirzepatideDimitrios Patoulias, Christodoulos Papadopoulos, Nikolaos Fragakis, et al.
Nefrologia|December 9, 2022
Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fractionDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Pageof 13